Health Minister has approved the listing of Pasireotide on the Pharmaceutical Benefits Scheme in Australia. The $10million subsidy means patients will get access to Pasireotide for $38.30 or $6.20 with a concession.
Pegvisomant (Somavert) is an injectable medication used in the treatment of uncontrolled acromegaly, where therapies used (which are very effective) have failed to meet the desired effect in some patients. The PBS listing of this new treatment for acromegaly from the 1st of September is welcomed news for patients with acromegaly.
As Acromegaly is a debilitating disease that at times cannot be adequately controlled by current available subsided therapies, Australian Pituitary Foundation welcomes the accessibility of an additional subsidised treatment in Australia.
Due to the reduced life expectancy of patients with Acromegaly, effective management of the disease is critical to enable the best possible outcome for the patient.
With so many associated complications caused by excess Growth Hormone circulating through the body, patients experience a very low quality of life, which has a flow on impact to their families who are supporting them emotionally, and at times financially and physically.
This disease causes a multitude of associated complications including overgrowth of soft tissues and internal organs, bone, joint, vertebrate changes and cardiovascular complications. The consequential physical changes have implications on a patient’s self-esteem and general sense of well-being.
The Australian Pituitary Foundation’s mission is to support and educate people impacted by pituitary conditions, one being Acromegaly. We convey awareness and provide relevant information to the general and medical communities and act as a collective voice for pituitary patients and their families.
Australian Pituitary Foundation commends the Minister for Health for the decision of approving an additional subsidised treatment for Acromegaly in Australia. This would provide patients whose previous therapies have failed, better access to an additional proven treatment option.
Increasing treatment options available to patients will allow more effective disease management and will potentially accelerate alleviating the debilitating symptoms, improving patient’s quality of life, life expectancy and also have positive flow on effects to the patient’s families and day to day life.
Thank you to Stephanie who agreed to be interviewed,
And to Claire and Pete who assisted with our consumer campaign to support the Pegvisomant submission.
Click here to view Claire
Clickhere to view Pete
Read our newsletters which discuss different aspects of too much growth hormone circulating the human body.